BioCryst Pharmaceuticals, Inc.
Human plasma kallikrein inhibitors

Last updated:

Abstract:

Disclosed are compounds of formula I: ##STR00001## as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one such compound, and methods involving use of the compounds and compositions in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.

Status:
Grant
Type:

Utility

Filling date:

10 Apr 2020

Issue date:

25 Jan 2022